GSK’s GSK respiratory syncytial virus vaccine for older adults may protect against disease for two full RSV seasons, according to new results from a phase 3 trial the company released Wednesday. Similar efficacy was seen over two seasons in adults with underlying comorbidities and advancing age, the company said in a release. The U.S. Food and Drug Administration in May approved the vaccine, Arexvy, for prevention of RSV in people 60 and older. RSV is a highly contagious virus that causes lung and breathing-passage infections. GSK’s ADR is down 1.5% in the year to date, while the S&P 500 is up 14%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.